Multiple sclerosis physical examination: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 15: Line 15:


==== Internuclear Ophthalmoplegia ====
==== Internuclear Ophthalmoplegia ====
Internuclear ophtalmoplegia (INO) is defined as a gaze problem. Lesions in medial longitudinal fasciculus in brain stem are known to be the cause of INO.
Internuclear ophtalmoplegia (INO) is defined as a gaze problem. Lesions in medial longitudinal fasciculus in brain stem are known to be the cause of INO.<ref name="pmid11552000">{{cite journal |vauthors=Frohman EM, Zhang H, Kramer PD, Fleckenstein J, Hawker K, Racke MK, Frohman TC |title=MRI characteristics of the MLF in MS patients with chronic internuclear ophthalmoparesis |journal=Neurology |volume=57 |issue=5 |pages=762–8 |date=September 2001 |pmid=11552000 |doi= |url=}}</ref>


====Optic Neuritis====
====Optic Neuritis====

Revision as of 14:59, 1 March 2018

Multiple sclerosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple sclerosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography or Ultrasound

CT Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Alternative Therapies

Primary Prevention

Secondary Prevention

Tertiary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Multiple sclerosis physical examination On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple sclerosis physical examination

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple sclerosis physical examination

CDC on Multiple sclerosis physical examination

Multiple sclerosis physical examination in the news

Blogs on Multiple sclerosis physical examination

Directions to Hospitals Treating Multiple sclerosis

Risk calculators and risk factors for Multiple sclerosis physical examination

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Physical Examination

Physical examination of patients with multiple sclerosis is usually remarkable for:

Lhermitte's Sign

About 25-40% of MS patients experience lhermitte’s sign as an electrical shock sensation going downward from neck when the patients neck bends forward. Lhermitte sign can correlate with MRI abnormalities of caudal medulla or cervical dorsal columns. .[1][2][3][4]

Spasticity and increased reflexes

Damage to the upper motor neurons and decrease inhibition of lower motor neurons in MS can increase muscle tone and rigidity in 75% of MS patients.[5]

Internuclear Ophthalmoplegia

Internuclear ophtalmoplegia (INO) is defined as a gaze problem. Lesions in medial longitudinal fasciculus in brain stem are known to be the cause of INO.[6]

Optic Neuritis

Optic neuritis can be the first sign of multiple sclerosis especially when it’s accompanied by white matter MRI lesions and is very common among these patients.[7][8]

References

  1. Gutrecht JA, Zamani AA, Slagado ED (1993). "Anatomic-radiologic basis of Lhermitte's sign in multiple sclerosis". Arch. Neurol. 50 (8): 849–51. PMID 8352672.
  2. Al-Araji AH, Oger J (2005). "Reappraisal of Lhermitte's sign in multiple sclerosis". Mult. Scler. 11 (4): 398–402. PMID 16042221.
  3. Sandyk R, Dann LC (1995). "Resolution of Lhermitte's sign in multiple sclerosis by treatment with weak electromagnetic fields". Int. J. Neurosci. 81 (3–4): 215–24. PMID 7628912.
  4. Kanchandani R, Howe JG (1982). "Lhermitte's sign in multiple sclerosis: a clinical survey and review of the literature". J. Neurol. Neurosurg. Psychiatr. 45 (4): 308–12. PMID 7077340.
  5. Boissy AR, Cohen JA (September 2007). "Multiple sclerosis symptom management". Expert Rev Neurother. 7 (9): 1213–22. doi:10.1586/14737175.7.9.1213. PMID 17868019.
  6. Frohman EM, Zhang H, Kramer PD, Fleckenstein J, Hawker K, Racke MK, Frohman TC (September 2001). "MRI characteristics of the MLF in MS patients with chronic internuclear ophthalmoparesis". Neurology. 57 (5): 762–8. PMID 11552000.
  7. Beck RW, Trobe JD (1995). "What we have learned from the Optic Neuritis Treatment Trial". Ophthalmology. 102 (10): 1504–8. PMID 9097798.
  8. "The 5-year risk of MS after optic neuritis: experience of the optic neuritis treatment trial. 1997". Neurology. 57 (12 Suppl 5): S36–45. 2001. PMID 11902594.

Template:WH Template:WS